The clinical trials that put GLP-1 medications on the map enrolled people with BMIs of 30 and above — or 27+ with weight-related health conditions. The headlines are all about dramatic transformations: 50 lbs lost, 20% body weight reductions, before-and-after photos that look like different people.

But what about the person at BMI 23 who wants to drop from 175 to 165? The one who's already in decent shape but can't seem to shed that last layer of softness around the midsection? The one who's been eating well and training consistently but wants to get from "fit" to "lean"?

This is the question nobody in the medical establishment wants to talk about directly — and the one a lot of people are quietly asking. Let's look at what the data actually says.

What the Clinical Data Shows (and Doesn't Show) at Lower BMIs

Here's the honest answer: there are no large-scale randomized controlled trials of semaglutide or tirzepatide specifically in people with BMIs of 22–25. The landmark STEP trials that demonstrated 15–17% body weight loss with semaglutide 2.4mg enrolled participants with BMI ≥30 (or ≥27 with a comorbidity). The SURMOUNT trials for tirzepatide had similar inclusion criteria.

That said, we're not flying completely blind. Several things we do know:

  • The mechanism works regardless of starting weight. GLP-1 medications suppress appetite by acting on the hypothalamus and slow gastric emptying. These effects aren't BMI-dependent — they work whether you're 300 lbs or 170 lbs. If you eat less, you'll lose weight. The question is whether the drug is worth it for a smaller target.
  • Sub-analysis of lower-BMI participants exists. In the STEP trials, participants in the lower end of the BMI range (27–30) still lost significant weight — though somewhat less in percentage terms than those starting at higher BMIs. A 2023 analysis published in The Lancet found that baseline BMI modestly influenced the percentage of weight lost, but the drug was effective across the full range studied.
  • Off-label prescribing at lower BMIs is widespread. Endocrinologists and obesity medicine specialists report prescribing semaglutide to patients with BMIs in the 24–27 range, particularly those who carry visceral fat, have metabolic risk factors, or have struggled to lose a specific amount through diet and exercise alone. The results are generally positive, though formal data is limited.

For a broader look at the trial data behind GLP-1 weight loss, see our semaglutide clinical data breakdown.

Lower Doses for Leaner Bodies

One of the key differences when using GLP-1 medications at a lower BMI is dosing. The standard Wegovy protocol ramps up to 2.4mg/week of semaglutide. But many providers prescribing for leaner patients keep the dose lower — often 0.5mg or 1.0mg/week, which is more in line with Ozempic dosing for diabetes.

The rationale makes sense: if you only need to lose 10–15 lbs, you don't need the maximum appetite-suppressive effect. A lower dose can reduce food noise and cravings just enough to push past a plateau without the more intense side effects (nausea, gastrointestinal distress) that often accompany higher doses. Many patients at lower BMIs report that 0.5mg of semaglutide feels like "enough" — the constant background chatter about food quiets down, portions naturally decrease, and the last few pounds start to come off without heroic effort.

Body Recomposition vs. Pure Weight Loss

This is where the conversation for lean users fundamentally diverges from the standard GLP-1 narrative. When someone at BMI 35 loses 40 lbs, the goal is straightforward weight loss — and the health benefits are enormous. When someone at BMI 23 loses 10 lbs, the goal is usually body recomposition: less fat, maintained or increased muscle, more definition.

Here's the challenge: GLP-1 medications cause weight loss through reduced caloric intake. And any caloric deficit — whether from GLP-1, dieting, or both — results in some loss of lean mass alongside fat. Research suggests that roughly 25–40% of weight lost through caloric restriction alone is lean mass. For a detailed look at this issue, see our article on GLP-1 and muscle loss.

If you're at BMI 23 and lose 10 lbs, losing 3–4 lbs of that as muscle would be counterproductive — you'd end up lighter but not necessarily leaner-looking. This is why resistance training and adequate protein intake are non-negotiable for lean users considering GLP-1 therapy. The drug handles the appetite side; you need to handle the muscle-preservation side.

Practical protocols for lean users typically include:

  • Protein intake of 1.4–1.6g per kg of body weight daily (higher than the general recommendation)
  • Progressive resistance training 3–4x per week — this is the single most important factor in preserving lean mass during a deficit
  • Creatine monohydrate (3–5g/day) — well-supported for maintaining strength and lean mass during caloric restriction
  • Moderate caloric deficit — the lower dose helps ensure you're not in too steep a deficit, which preserves more muscle

Risks and Considerations at Low Body Fat

Using GLP-1 medications when you're already lean isn't without downsides:

  • Muscle loss is proportionally more significant. Losing 3 lbs of muscle matters a lot more at 170 lbs than at 280 lbs.
  • "Ozempic face" is more visible on lean people. Facial fat loss that's barely noticeable on someone starting at a high weight can create a gaunt, aged look on someone who was already slim. This is a real concern, especially for women. Learn more in our piece on Ozempic face.
  • The benefit-to-side-effect ratio shifts. GLP-1 side effects (nausea, constipation, fatigue) are the same regardless of your starting weight. When you're losing 50 lbs, those side effects feel like a worthwhile trade. When you're trying to lose 10, the calculus changes.
  • No FDA approval for this use case. Prescribing GLP-1 at BMI 22–25 is off-label. This means insurance almost certainly won't cover it, and you'll be paying out-of-pocket — likely through a telehealth provider offering compounded semaglutide.

Who It Makes Sense For

Based on the available evidence and clinical practice patterns, GLP-1 medication at a healthy BMI may be reasonable if:

  • You've been consistently training and eating well for 6+ months but can't break through a plateau
  • You carry disproportionate visceral fat (the "skinny fat" pattern — normal BMI but elevated waist circumference or body fat percentage)
  • You have metabolic risk factors despite a normal BMI (elevated fasting glucose, insulin resistance, high triglycerides)
  • You understand it's a short-term tool (2–4 months at low dose), not a lifestyle
  • You're committed to resistance training and high protein intake to preserve muscle

Who Should Skip It

  • Anyone with a BMI under 18.5 — you do not need to lose weight, and GLP-1 would be genuinely harmful
  • Anyone with a history of eating disorders — the appetite suppression effects can reinforce disordered patterns
  • Anyone looking for a shortcut to avoid training — if you haven't been consistently lifting and eating well, start there first
  • Anyone who can't commit to muscle-preservation protocols — losing 10 lbs of mixed fat and muscle at a healthy weight is a net negative

See What It Would Look Like on You

If you're in the healthy BMI range and curious what dropping that last layer would look like, the MeOnGLP tool can show you. It adjusts projections for leaner users — expecting a 5–10% reduction rather than the larger losses projected for higher BMIs. The result is subtle but real: a tighter midsection, more facial definition, the kind of change where people notice something's different but can't quite pin down what.

It won't tell you whether GLP-1 medication is right for your specific situation — that's a conversation with a provider who knows your full health picture. But it can answer the question everyone starts with: what would I actually look like?